Search Result

Pathways Recommended:	Anti-infection

Results for "

carbapenem-resistant bacterial infections

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (6) Antibiotic (1) Beta-lactamase (4) Toll-like Receptor (TLR) (1)
By Research Areas:	Infection (6) Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Targets Recommended: Bacterial

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147349

Pilabactam sodium ANT3310 sodium	Beta-lactamase Bacterial	Infection
Pilabactam (ANT3310) sodium is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC₅₀ values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam sodium potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam sodium can be used in the research of bacterial infection .

HY-125604

WCK-4234	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 lacks direct antibacterial activity. WCK-4234 inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

HY-147349A

Pilabactam ANT3310	Bacterial Beta-lactamase	Infection
Pilabactam (ANT3310) is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC₅₀ values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam can be used in the research of bacterial infection .

HY-125604A

WCK-4234 free base	Beta-lactamase Bacterial	Infection Inflammation/Immunology
WCK-4234 free base is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 free base lacks direct antibacterial activity. WCK-4234 free base inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 free base can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections .

HY-174852

Antibacterial agent 285	Antibiotic Bacterial	Infection
Antibacterial agent 285 (Compound 3) is a cephalosporin antibiotic. Antibacterial agent 285 has significant antibacterial activity against gram-negative bacterium with MICs of 0.125-0.5, 0.125-0.5 and 0.125-2 μg/mL for carbapenem-resistant Acinetobacter baumannii (CRAB), Klebsiella pneumoniae (CRE) and Pseudomonas aeruginosa (CRPA), respectively. Antibacterial agent 285 can be used for bacterial infection research, such as complicated urinary tract infections (cUTI) and kidney infections .

HY-P11580

Pap12-6-10	Toll-like Receptor (TLR) Bacterial	Infection
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize *bacterial* cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections .

Cat. No.	Product Name

HY-L924

Boronic acid/boronic ester fragment library	1,488 compounds
Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy. To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

Boronic acid/boronic ester fragment library

1,488 compounds

Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy.

To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

Cat. No.	Product Name	Target	Research Area

HY-P11580

Pap12-6-10	Toll-like Receptor (TLR) Bacterial	Infection
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize *bacterial* cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.